LYRA THERAPEUTICS INC
NASDAQ: LYRA (Lyra Therapeutics, Inc.)
Kemas kini terakhir: 6 jam lalu0.010
0.00 (0.00%)
| Penutupan Terdahulu | 0.010 |
| Buka | 0.010 |
| Harga / Jualan (P/S) | 0.040 |
| Harga / Buku (P/B) | 7.10 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -4,347.54% |
| EPS Cair (TTM) | -60.50 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -65.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 861.47% |
| Nisbah Semasa (MRQ) | 2.96 |
| Aliran Tunai Operasi (OCF TTM) | -56.40 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -29.27 M |
| Pulangan Atas Aset (ROA TTM) | -28.54% |
| Pulangan Atas Ekuiti (ROE TTM) | -195.46% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Lyra Therapeutics, Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.5 |
| Purata | 0.17 |
|
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company’s operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.69% |
| % Dimiliki oleh Institusi | 40.31% |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |